lirilumab + nivolumab + ipilimumab

**lirilumab + nivolumab + ipilimumab** is an experimental triple combination immunotherapy regimen consisting of three monoclonal antibodies targeting distinct immune checkpoints. - **Lirilumab** is a fully human monoclonal antibody against inhibitory killer-cell immunoglobulin-like receptors (KIR) expressed on natural killer (NK) cells and some T cells, blocking inhibitory KIR and enhancing anti-tumor activity of NK cells[2][4]. - **Nivolumab** is a fully human IgG4 monoclonal antibody that blocks programmed death-1 (PD-1), a checkpoint that limits T-cell activation[1][4]. - **Ipilimumab** is a fully human IgG1 monoclonal antibody directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), inhibiting an immune suppressive pathway and promoting T-cell activation[1][4][5]. The combination is being investigated for the treatment of advanced solid tumors, primarily for its potential to generate a more comprehensive and synergistic activation of the immune response through distinct, non-redundant mechanisms[2][4]. It is an investigational therapy not currently approved for any indication as a triple combination, but individual and dual combinations are approved in several cancers.

Other names

lirilumab + Opdivo + Yervoy